---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007665"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:31:44.249940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients

## Summary
- Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.
- Operating loss $4.1M (Q1 2025) vs $3.1M (Q1 2024); R&D spending up $0.9M on APR-1051 and ATRN-119 trials.
- ATRN-119 ABOYA-119 trial: 3 patients at 550mg BID had tumor shrinkage of 7%, 14%, and 21% below RP2D.
- APR-1051 ACESOT-1051 trial enrolling at 100mg QD; next cohort 150mg; preliminary efficacy data expected H2 2025.
- Entered Material Transfer Agreement with MD Anderson to study APR-1051 in head and neck cancers.

## SEC filing metadata
- accession: 0001558370-25-007665
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/0001558370-25-007665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/apre-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007665
- JSON: https://secwatch.observer/filing/0001558370-25-007665.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.